Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease

Journal of Clinical Oncology

Volumn 25, Issue 25, 2007, Pages 3902-3907

  Advani, Ranjana ^a   Maeda, Lauren ^a   Lavori, Philip ^a   Quon, Andrew ^a   Hoppe, Richard ^a   Breslin, Sheila ^a   Rosenberg, Saul A ^a   Horning, Sandra J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; STANFORD V PROTOCOL; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; DISEASE COURSE; MEDIASTINUM TUMOR; PREDICTION AND FORECASTING; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DISEASE PROGRESSION; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; MECHLORETHAMINE; MEDIASTINAL NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREDNISONE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 34548541713     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9867     Document Type: Article

References (28)

1. Kostakoglu L, Goldsmith SJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears? Eur J Nucl Med 27:1564-1578, 2000
2. O'Doherty MJ, Macdonald EA, Barrington SF, et al: Positron emission tomography in the management of lymphomas. Clin Oncol (R Coll Radiol) 14:415-426, 2002
3. Schiepers C, Filmont JE, Czernin J: PET for staging in Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30:S82-S88, 2003
4. Naumann R, Beuthien-Baumann B, Reiss A, et al: Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 90:620-625, 2004
5. 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1356-1363, 2002
6. Mikhaeel NG, Hutchings M, Fields PA, et al: FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin's lymphoma. Ann Oncol 16:1514-1523, 2003
7. 18F]fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 106:1376-1381, 2005
8. Juweid ME, Wiseman GA, Vose JM, et al: Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652-4661, 2005
9. Filmont JE, Yap CS, Ko F, et al: Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease. Mol Imaging Biol 6:47-54, 2004
10. Hutchings M, Mikhaeel NG, Fields PA, et al: Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160-1168, 2005
11. Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
12. Horning SJ, Hoppe R, Advani R, et al: Efficacy and late effects of Stanford V chemotherapy with radiotherapy in untreated Hodgkin's disease: Mature data in early to advanced stage patients. Blood 104:308a, 2004 (abstr)
13. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
14. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
15. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin's disease Staging Classification. Cancer Res 31:1860-1861, 1971
16. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998
17. Spaepen K, Stroobants S, Dupont P, et al: Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish between Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272-278, 2001
18. 18F-fluorodeoxyglucose for post treatment evaluation in Hodgkin's Disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999
19. Naumann R, Vaic A, Beuthien-Baumann B, et al: Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 115:793-800, 2001
20. Weihrauch MR, Re D, Scheidhauer K, et al: Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin's disease. Blood 98:2930-2934, 2001
21. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 12:29-37, 2001
22. Guay C, Lepine M, Verreault J, et al: Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 44:1225-1231, 2003
23. Meyer R, Gospodarowicz M, Connors J, et al: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005
24. Gobbi PG, Levis A, Chisesi T, et al: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate-and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198-9207, 2005
25. Advani R, Maeda L, Hoppe R, et al: Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V + radiotherapy (RT) experience. Blood 106:1932a, 2005 (abstr)
26. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
27. Gallamani A, Rigacci L, Merli F, et al: The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Hematologica 91:475-481, 2006
28. Dann EJ, Shalom RB, Tamir A, et al: Risk adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high risk Hodgkin lymphoma with no impairment of outcome. Blood 109:905-909, 2007